Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06350526
Status:
RECRUITING
Last Update Posted:
2024-04-05
First Post:
2024-02-01
Brief Title:
Radiological Characterization of Pulmonary Involvement in Patients With Hematological Diseases
Sponsor:
New Valley University
Organization:
New Valley University
Study Overview
Official Title:
Radiological Characterization of Pulmonary Involvement in Patients With Hematological Diseases
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hematologic malignancies are heterogeneous groups of neoplasia with frequent pulmonary complications These complications may be secondary to the patients comorbidities to the hemopathy itself or its treatments Divided into infectious and non-infectious complications the etiologies are numerous and varied This makes the diagnostic approach complex for the clinicians
Detailed Description:
Although infectious processes of the lungs are common in these immunosuppressed patient collectives non-infectious causes account for up to half of the pulmonary manifestations found in hematologic malignancies Besides the frequent infections including opportunistic pathogens a broad differential diagnosis including drug-induced lung injury by cytostatic substances cytokines and innovative immunotherapeutic agents rarer transfusion of blood products and intrathoracic manifestations of the hematologic malignancy itself must be kept in mind Finally vascular complications can also lead to pulmonary reactions Early and consistent diagnostics and treatment of bronchopulmonary intrathoracic and vascular complications within the framework of hematologic systemic diseases can be essential for the patients prognosis Up to 25 of patients with profound neutropenia lasting for 10 days develop lung infiltrates which frequently do not respond to broad-spectrum antibacterial therapy While a causative pathogen remains undetected in most cases Aspergillus spp Pneumocystis jirovecii multi-resistant Gram-negative pathogens mycobacteria or respiratory viruses may be involved In at-risk patients who have received trimethoprim-sulfamethoxazole TMPSMX prophylaxis filamentous fungal pathogens appear to be predominant yet commonly not proven at the time of treatment initiation
In patients who do not improve rapidly with first-line therapy with broad spectrum antibiotics cross-sectional thoracic CT imaging is essential It provides much better definition of the pattern of radiological changes that includes three main groups consolidation nodules micro- and macro- and diffuse changes as ground glass pattern Discuss these radiological patterns and how this guides the appropriate initial investigations and treatment options will be of a great value to be followed
In patients who do not improve rapidly with first-line therapy with broad spectrum antibiotics cross-sectional thoracic CT imaging is essential It provides much better definition of the pattern of radiological changes that includes three main groups consolidation nodules micro- and macro- and diffuse changes as ground glass pattern Discuss these radiological patterns and how this guides the appropriate initial investigations and treatment options will be of a great value to be followed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None